In this article, we challenge 2 fundamental assumptions underlying the current regulation of research for unproven therapies: (1) current regulatory practices serve the best interests of patients and (2) standard definitions allow clear demarcation and rational regulation of such therapies in clinical practice, research, and quality improvement (QI) activities. Our goal is to prompt serious con...
